Characteristics of patients entering the randomisation phase
| Characteristics | Etanercept 50 mg (n = 7) | Placebo (n = 6) | Mean difference (95% CI) or χ2 P value |
|---|---|---|---|
| Mean age, years (SE) | 73.4 (2.3) | 74.8 (2.9) | 1.4 (−6.7 to 9.5) yrs P = 0.7 |
| Men, n (%) | 5 (71) | 4 (66) | χ2 0.03 P = 0.9 |
| Disease duration, years (SE) | 3.4 (1.2) | 5.3 (1.1) | 1.9 (−1.8 to 5.6) yrs P = 0.3 |
| MoCA pts (SE) | 21.1 (1.6) | 24.7 (1.0) | 3.5 (−0.6 to 7.6) pts P = 0.09 |
| FCSRT pts (SE) | 36.4 (4.3) | 46.8 (1.0) | 10.4 (−0.03 to 20.8) pts P = 0.051 |
| RBANS pts (SE) | 82.0 (2.9) | 88.3 (4.6) | 6.3 (−0.5 to 18.0) pts P = 0.3 |
| ADCS-ADL MCI pts (SE) | 38.9 (2.9) | 43.5 | 4.6 (−3.1 to 12.4) pts P = 0.2 |
CI: confidence interval; pts: patients; se: standard error; yrs: years